|1st December 2020||Michael A Metzger||15,000||Open or private sale||$22.97||$344,512.50|
|1st December 2020||Michael A Metzger||15,000||Exercise of derivative||$7.20||$108,000.00|
|23rd November 2020||Peter Ordentlich||5,684||Open or private sale||$23.33||$132,602.60|
|23rd November 2020||Peter Ordentlich||7,954||Open or private sale||$23.58||$187,594.29|
|23rd November 2020||Peter Ordentlich||5,684||Exercise of derivative||$3.08||$17,506.72|
|23rd November 2020||Peter Ordentlich||16,334||Open or private sale||$22.89||$373,924.46|
|23rd November 2020||Peter Ordentlich||24,288||Exercise of derivative||$3.08||$74,807.04|
|10th November 2020||Briggs Morrison||17,466||Open or private sale||$20.06||$350,312.07|
|10th November 2020||Briggs Morrison||17,466||Exercise of derivative||$7.20||$125,755.20|
|9th November 2020||Briggs Morrison||62,938||Open or private sale||$20.04||$1,261,264.93|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005.